JEFFREY GRANETT, MD
Osteopathic Medicine at Boxwood Rd, Rosemont, PA
License number
Pennsylvania MD038305E
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
411 Boxwood Rd, Rosemont, PA 19010
Phone
(610) 525-4977
(610) 525-9717 (Fax)
(610) 525-9717 (Fax)
Personal information
See more information about JEFFREY GRANETT at radaris.comName
Address
Phone
411 Boxwood Rd, Bryn Mawr, PA 19010
411 Boxwood Rd, Bryn Mawr, PA 19010
Organization information
See more information about JEFFREY GRANETT at bizstanding.comJeffrey Granett MD
411 Boxwood Rd, Bryn Mawr, PA 19010
Industry:
Internist
Phone:
(610) 525-4977 (Phone)
Jeffrey Roger Granett
Professional information
Composition Comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)Ethoxy]Benzyl] Thiazolidine-2,4-Dione
US Patent:
2004008, Apr 29, 2004
Filed:
Nov 19, 2003
Appl. No.:
10/716923
Inventors:
Jeffrey Granett - Rosemont PA, US
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - Research Triangle Park NC, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - Research Triangle Park NC, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
International Classification:
A61K031/4439
US Classification:
514/342000
Abstract:
A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
Composition Comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dione
US Patent:
2004018, Sep 16, 2004
Filed:
Mar 24, 2004
Appl. No.:
10/808014
Inventors:
Jeffrey Granett - Rosemont PA, US
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - King of Prussia PA, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - King of Prussia PA, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
International Classification:
A61K031/4439
US Classification:
514/342000
Abstract:
A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
Composition Comprising 5-[4-[2-(N-Methyl-N-2-Pyridy)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dione
US Patent:
2002017, Nov 28, 2002
Filed:
Feb 5, 2002
Appl. No.:
10/068514
Inventors:
Jeffrey Granett - Rosemont PA, US
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - , US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - , US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
Assignee:
SmithKline Beecham p.I.c.
International Classification:
A61K031/4439
US Classification:
514/340000
Abstract:
A pharmaceutical composition comprising Compound (1), characterised in that the composition comprises 2 to 12 mg of Compound (1) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
Composition Comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dione
US Patent:
2003018, Oct 2, 2003
Filed:
Mar 21, 2003
Appl. No.:
10/394858
Inventors:
Jeffrey Granett - Rosemont PA, US
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - Research Triangle Park NC, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
Hamish Ross - Berwyn PA, US
Jaikrishna Patel - Research Triangle Park NC, US
Robin Price - Great Dunmow, GB
Paul Wray - Crawley, GB
International Classification:
A61K031/4439
US Classification:
514/342000
Abstract:
A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.